The Japanese Journal of Pharmacology
Online ISSN : 1347-3506
Print ISSN : 0021-5198
ISSN-L : 0021-5198
Immunopharmacological Studies on TBX, a New Antiallergic Drug (4) Effects on Type II to IV Allergic Reactions and Immunological Functions in Animal Models
Yukiyoshi YANAGIHARAHiroshi KASAIToshio KAWASHIMAKenji NINOMIYA
Author information
JOURNAL FREE ACCESS

1989 Volume 51 Issue 1 Pages 93-100

Details
Abstract
The effects of 9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1, 2-a]pyrimidin-4-one potassium salt (TBX) on type II to IV allergic reactions and immunological functions were investigated in animal models. Types II to IV allergic reactions in rodents were unaffected in vivo by TBX, even at higher doses than those capable of completely inhibiting the type I allergic reaction. However, both complement-mediated hemolysis via the classical pathway and hypotonic shock-induced hemolysis were slightly inhibited in vitro only by a high concentration of the drug (10-4 g/ml). In the mouse system, TBX had no ability to suppress anti-hapten IgE anti-body formation as well as hemagglutinin formation and to inhibit the proliferation of spleen cells induced by non-specific T and B cell mitogens. The results obtained indicate that TBX is an antiallergic drug essentially devoid of inhibitory actions on types II to IV allergic reactions and immunological functions, thus indicating that it is a specific inhibitor of type I allergic reactions.
Content from these authors
© The Japanese PharmacologicalSociety
Previous article Next article
feedback
Top